Âé¶¹´«Ã½

    Advertisement
    The Independent17:44Novo Nordisk FDA Pharma
    Fox News17:55Novo Nordisk FDA Pharma
    The Times of India16:13Donald Trump
    The Independent14:48Donald Trump
    EasternEye05:31Tirzepatide
    The Tribune, California15:50Tirzepatide
    Scientific American08:49Pharma Global Health Novo Nordisk
    WA Today18:48Mounjaro Eli Lilly Pharma
    The Seattle Times11:12Mounjaro Eli Lilly Pharma
    Indian Express04:05Kapil Sharma Karan Johar India
    The Economic Times12:00Kapil Sharma Karan Johar India
    The Motley Fool04:38Eli Lilly Novo Nordisk Pharma
    letsrecycle.com04:52Global Health
    i News07:40Global Health
    Hindustan Times12:24Lizzo Indian Entertainment
    The Economic Times12:44Lizzo Indian Entertainment
    Evening Standard09:05Alzheimer's
    Evening Standard13:05Alzheimer's
    In the last hour
    NPR07:04
    In the last 2 hours
    Vogue06:09
    Earlier today
    Yahoo! UK & Ireland01:17
    The Scientist00:18
    Yesterday
    The Irish Independent21:41 23-Apr-25
    The Independent17:44 23-Apr-25
    The Times of India16:13 23-Apr-25
    UNILAD16:03 23-Apr-25
    The Economic Times12:44 23-Apr-25
    Hindustan Times12:24 23-Apr-25
    University at Buffalo11:55 23-Apr-25
    UNILAD10:17 23-Apr-25
    LADbible10:14 23-Apr-25
    Law.com10:12 23-Apr-25
    UNILAD06:32 23-Apr-25
    LADbible05:39 23-Apr-25
    letsrecycle.com04:52 23-Apr-25
    LADbible04:38 23-Apr-25
    Business Plus Online04:18 23-Apr-25
    National World04:05 23-Apr-25
    In the last 7 days
    This is Money17:17 22-Apr-25
    Law.com13:40 22-Apr-25
    Medpage Today13:13 22-Apr-25
    MailOnline12:36 22-Apr-25
    The Motley Fool12:20 22-Apr-25
    Gizmodo12:14 22-Apr-25
    PR Newswire (Press Release)12:01 22-Apr-25
    UNILAD11:11 22-Apr-25
    The Times of India10:43 22-Apr-25
    Macau Business10:43 22-Apr-25
    The Motley Fool08:47 22-Apr-25
    Evening Standard06:45 22-Apr-25
    MailOnline21:04 21-Apr-25
    Psychology Today17:26 21-Apr-25
    Law36016:32 21-Apr-25
    The Tribune, California15:50 21-Apr-25
    Scrip Pharma Intelligence15:47 21-Apr-25
    The Independent14:48 21-Apr-25
    BioPharma Dive12:24 21-Apr-25
    Green Queen11:35 21-Apr-25
    Health Magazine09:23 21-Apr-25
    Scientific American08:49 21-Apr-25
    The Motley Fool04:38 21-Apr-25
    MailOnline12:54 20-Apr-25
    Futurism12:16 20-Apr-25
    GlobeNewswire (Press Release)08:00 20-Apr-25
    UNILAD07:00 20-Apr-25
    Hindustan Times06:16 20-Apr-25
    LADbible10:45 19-Apr-25
    Evening Standard09:05 19-Apr-25
    Knowridge Science Report06:05 19-Apr-25
    HELLO!03:01 19-Apr-25
    Greek Reporter21:04 18-Apr-25
    The Economic Times20:11 18-Apr-25
    Futurism15:03 18-Apr-25
    Metro.co.uk14:50 18-Apr-25
    Pharmacy Times13:35 18-Apr-25
    MailOnline11:46 18-Apr-25
    MailOnline08:06 18-Apr-25
    i News07:40 18-Apr-25
    PR Newswire (Press Release)06:03 18-Apr-25
    GlobeNewswire (Press Release)05:25 18-Apr-25
    Daily Record05:20 18-Apr-25
    NewsBytes05:18 18-Apr-25
    allkpop05:12 18-Apr-25
    Indian Express04:05 18-Apr-25
    The Japan Times23:45 17-Apr-25
    Law36022:16 17-Apr-25
    MailOnline20:13 17-Apr-25
    WA Today18:48 17-Apr-25
    L.A. Taco17:49 17-Apr-25
    Benzinga16:48 17-Apr-25
    HumanProgress16:45 17-Apr-25
    NewsMax16:07 17-Apr-25
    Benzinga15:36 17-Apr-25
    Bloomberg Law15:26 17-Apr-25
    ITV14:28 17-Apr-25
    Live Science14:25 17-Apr-25
    FOX13 Seattle13:55 17-Apr-25
    Journal of American Medical Associations12:46 17-Apr-25
    MailOnline12:16 17-Apr-25
    The Economic Times12:00 17-Apr-25
    Business Insider11:50 17-Apr-25
    Quartz11:29 17-Apr-25
    FitnessVolt11:17 17-Apr-25
    The Seattle Times11:12 17-Apr-25
    Forbes10:53 17-Apr-25
    GlobeNewswire (Press Release)10:22 17-Apr-25
    Business Insider10:08 17-Apr-25
    UNILAD09:40 17-Apr-25
    Hindustan Times09:17 17-Apr-25
    Proactive Investors (US)09:08 17-Apr-25
    London South East08:48 17-Apr-25
    Yahoo! US08:23 17-Apr-25
    Prevention.com08:00 17-Apr-25
    The Times of India07:10 17-Apr-25
    Black Enterprise06:35 17-Apr-25
    GlobeNewswire (Press Release)05:40 17-Apr-25
    The Times of India01:32 17-Apr-25
    The Economic Times00:39 17-Apr-25
    In the last month
    Mint20:08 16-Apr-25
    Fox News17:55 16-Apr-25
    Deseret Morning News, Utah16:48 16-Apr-25
    The Conversation (UK)16:18 16-Apr-25
    NPR16:07 16-Apr-25
    Vice (US)15:02 16-Apr-25
    Cleveland 1913:32 16-Apr-25
    Lexington Herald-Leader, Kentucky13:05 16-Apr-25
    The Times of India13:00 16-Apr-25
    Pharmaceutical Technology11:18 16-Apr-25
    Irish Examiner10:38 16-Apr-25
    The Financial Express09:46 16-Apr-25
    PR Newswire (Press Release)07:08 16-Apr-25
    MailOnline06:45 16-Apr-25
    NewsBytes05:37 16-Apr-25
    view more headlines
    24 Apr 07:04

    About our Ozempic news

    Latest news on Ozempic, Wegovy, Rybelsus: semaglutide weight loss drugs making headlines for remarkable results, high demand, and celebrity use. Stay updated on these popular GLP-1 medications.

    Ozempic, Wegovy, and Rybelsus are brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes treatment. These injectable and oral medications have gained significant attention for their impressive weight loss effects, with many users reporting rapid and substantial body weight reductions. As a result, demand for semaglutide drugs has skyrocketed, leading to shortages and waiting lists in some areas.

    Our semaglutide news feed brings you the latest updates on these groundbreaking weight loss drugs from reliable medical sources, pharmaceutical companies like Novo Nordisk, and real-world patient experiences. Stay informed about the efficacy, safety, and potential side effects of Ozempic, Wegovy, and Rybelsus, as well as ongoing clinical trials and research into their long-term effects and potential new applications.

    In addition to their medical aspects, semaglutide drugs have become a cultural phenomenon, with celebrities and influencers openly discussing their use of Ozempic and Wegovy for weight loss. Our feed covers these high-profile endorsements and the ensuing public discourse about the ethics and accessibility of these treatments. We also explore the societal implications of the growing popularity of semaglutide, including its impact on body image standards and the potential for exacerbating existing inequalities in healthcare access.

    As the demand for Ozempic, Wegovy, and Rybelsus continues to grow, our feed keeps you updated on supply chain issues, regulatory developments, and efforts by manufacturers to ramp up production and expand availability. We also cover debates surrounding insurance coverage for these weight loss drugs and the evolving policies of healthcare providers and payers.

    With obesity rates on the rise globally, the advent of effective weight loss medications like semaglutide has significant implications for public health and healthcare systems. Our semaglutide news feed delves into these broader contexts, exploring the potential of these drugs to combat the obesity epidemic and their role in comprehensive weight management strategies alongside lifestyle changes and other interventions.

    Stay at the forefront of the rapidly evolving landscape of semaglutide weight loss treatments with our continuously updated Ozempic, Wegovy, and Rybelsus news feed. Whether you're a healthcare professional, a person struggling with obesity, or simply interested in this groundbreaking development, our feed is your go-to source for comprehensive, nuanced coverage of these remarkable drugs.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.